Dart Neuroscience, (cayman) Ltd.

Ligand Pharmaceuticals, Inc.

Dart Neuroscience, LLC

Jillian Basinger

Lino J Valdez

Vincent Santora

Alan P Kaplan

Andrew Richard Hudson

Varsha Gupta

Dipanjan Sengupta

Benjamin Pratt

Graeme Freestone

Lin Zhi

Cornelis Arjan Van Oeveren

Yixing Shen

Jason Conrad Pickens

Steven L Roach

Chi Ching Mak

Mi Chen

Brett C Bookser

Bijan Pedram

Virginia Heather Sharron Grant

Joel Renick

James Na

Chi-Ching Mak

DeMichael Chung

Virgina H Grant

Catalina Cuervo

Jason C Pickens

Lino Valdez

The invention provides a chemical entity of Formula (I) wherein R, R, R, R, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence. 

Substituted azetidinyl compounds as GlyT1 inhibitors

The invention provides a chemical entity of Formula (I) wherein R, R, R, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

Substituted naphthyridine and quinoline compounds as MAO inhibitors

The invention provides a chemical entity of Formula (I), wherein R, R, R, R, Rand X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence. 

Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

Hematopoietic growth factor mimetic small molecule compounds and their uses

The invention provides a chemical entity of Formula (I) 

Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors

Growing community of inventors

San Diego, CA, United States of America

Jillian Basinger